JPMorgan Chase & Co. Reiterates Overweight Rating for Hikma Pharmaceuticals Plc (HIK)
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “overweight” rating reiterated by equities researchers at JPMorgan Chase & Co. in a research report issued on Thursday. They currently have a GBX 1,900 ($31.87) price objective on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 9.26% from the company’s current price.
Hikma Pharmaceuticals Plc (LON:HIK) opened at 1745.0001 on Thursday. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1004.00 and a 1-year high of GBX 1835.00. The stock’s 50-day moving average is GBX 1736. and its 200-day moving average is GBX 1583.. The company’s market cap is £3.451 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday. Finally, analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,600 ($26.84) to GBX 1,610 ($27.01) in a research note on Friday, August 1st. They now have a “hold” rating on the stock. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of GBX 1,770 ($29.69).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.